Article
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Apr 2018
Del Rosario Michael, Tsai Henry, Dasanu Constantin A
Abstract excerpt
Primary myelofibrosis is characterized by bone marrow fibrosis, splenomegaly and presence of JAK-2 V617F mutation in more than 90% of patients. Ruxolitinib is a Janus kinase inhibitor used for the treatment of primary myelofibrosis. We describe herein a persistent foot ulcer development attributed to ruxolitinib therapy. We are unaware of any previous reports of this phenomenon in the scientific literature. A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.